ACM
BIIB icon

Arlington Capital Management’s Biogen BIIB Stock Holding History

Arlington Capital Management’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-8,116
Closed -$2.25M – 85
2022
Q4 		$2.25M Buy
+8,116
New +$2.29M 2.51% 14

Other funds holding BIIB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Arlington Capital Management's BIIB Position: Q1 2023 in Review

Arlington Capital Management sold out of Biogen (BIIB) in Q1 2023, closing a stake of 8,116 shares — an estimated $2.25M sold.

Arlington Capital Management first reported a position in BIIB in Q4 2022 and held it in 1 quarter. The position peaked at $2.25M in Q4 2022. 1,001 funds tracked by Wall St. Rank hold BIIB as of Q1 2023.

  • Arlington Capital Management reported no remaining Biogen position as of Q1 2023 after selling out during the quarter.
  • Arlington Capital Management sold 8,116 Biogen shares in Q1 2023, an estimated $2.25M.
  • Arlington Capital Management first reported a position in Biogen in Q4 2022 and held it in 1 quarter.
  • Arlington Capital Management's Biogen position peaked at $2.25M in Q4 2022.
  • 1,001 funds tracked by Wall St. Rank held Biogen as of Q1 2023.

Based on Arlington Capital Management's 13F filing for Q1 2023, filed 15 May 2023.